Skip to main content
Reimbursement strategy

Market Access Strategy for Medical Devices in Europe

Strategic recommendations on the topic of market access pathways for medical devices and IVD tests

Learn more

White Paper: Innovative Payment Schemes for Medical Devices

Get insights from MTRC White Papers to discover a comprehensive summary of innovative payment schemes for medical devices, enabling direct applications by the MedTech industry

Request free of charge
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

A new coverage with evidence development scheme was announced in the Netherlands

In July 2025, the Dutch Healthcare Institute (ZIN) announced the establishment of a new policy framework named “Reimbursement within Research” (Vergoeding in Onderzoek). This framework allows temporary reimbursement from basic health insurance for existing care with insufficient evidence of effectiveness, conditional on further collection of evidence for evaluation. The policy will apply to specialist medical care, paramedical care, and medical devices.

Before applying the policy framework, ZIN will conduct an implementation review to define the processes, assess feasibility, and estimate potential risks. The draft implementation assessment is planned to be published by August 31, 2025. Stakeholders will be invited to provide feedback in September 2025. 

The launch of the new framework is scheduled for November 1, 2025. 

The full details in Dutch can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.